KARLA QUEIROZ
Dr. Karla Queiroz received her Ph.D. in 2011 at the Erasmus University in Rotterdam (Netherlands). She worked on signal transduction and chemoresistance in tumor diseases. As a postdoctoral researcher, she worked from 2010-2015 at Amsterdam UMC/AMC in the department of molecular and experimental medicine in the field of inflammation and cancer, and at the Flemish Institute for Biotechnology in Leuven in the field of vascular biology. During her postdoctoral studies, she focused on the role of constituents of the tumor microenvironment in tumor progression. She is (co-)author of 29 peer-reviewed publications. Currently, she works as Senior Scientist to develop in vitro 3D-organ models at the biotech company Mimetas BV, the Netherlands.
Selected publications:
Bruning U, Morales-Rodriguez F, Kalucka J, Goveia J, Taverna F, Queiroz KCS, Dubois C, Cantelmo AR, Chen R, Loroch S, Timmerman E, Caixeta V, Bloch K, Conradi LC, Treps L, Staes A, Gevaert K, Tee A, Dewerchin M, Semenkovich CF, Impens F, Schilling B, Verdin E, Swinnen JV, Meier JL, Kulkarni RA, Sickmann A, Ghesquière B, Schoonjans L, Li X, Mazzone M, Carmeliet P. Impairment of Angiogenesis by Fatty Acid Synthase Inhibition Involves mTOR Malonylation. Cell Metab. 2018; pii: S1550-4131(18)30462-5.
Schoors S, Bruning U, Missiaen R, Queiroz KC, Borgers G, Elia I, Zecchin A, Cantelmo AR, Christen S, Goveia J, Heggermont W, Goddé L, Vinckier S, Van Veldhoven PP, Eelen G, Schoonjans L, Gerhardt H, Dewerchin M, Baes M, De Bock K, Ghesquière B, Lunt SY, Fendt SM, Carmeliet PFatty acid carbon is essential for dNTP synthesis in endothelial cells.. Nature. 2015; 9, 520(7546):192-7.
Queiroz KCS, Shi K, Duitman JW, Aberson HL, Wilmink JW, van Noesel CJM, Richel DJ, Spek CA.Protease-activated receptor-1 drives pancreatic cancer progression and chemoresistance. Int J Cancer. 2014; Jan 16.
Horowitz NA, Blevins EA, Miller WM, Perry AR, Talmage KE, Mullins ES, Flick MJ, Queiroz KC, Shi K, Spek CA, Conway EM, Monia BP, Weiler H, Degen JL, Palumbo JS. Thrombomodulin is a determinant of metastasis through a mechanism linked to the thrombin binding domain but not the lectin-like domain. Blood. 2011 118(10):2889-95.
Queiroz KC, Ruela-de-Sousa RR, Fuhler GM, Aberson HL, Ferreira CV, Peppelenbosch MP, Spek CA. Hedgehog signaling maintains chemoresistance in myeloid leukemic cells. Oncogene. 2010; 29:6314-22.
Supervised Projects: